Top Markets
Coin of the day
Chinook Therapeutics, Inc. Chinook Therapeutics, Inc.

Chinook Therapeutics, Inc.

KDNY
Peringkat dalam Saham #7143
Chinook Therapeutics, Inc., a biotechnology enterprise in the clinical... Chinook Therapeutics, Inc., a biotechnology enterprise in the clinical development phase, is dedicated to the identification, progression, and market introduction of precise medical treatments for kidney-related conditions. The company's primary therapeutic candidate, atrasentan, is an endothelin receptor antagonist currently in Phase III clinical trials. This drug aims to treat IgA nephropathy and various other glomerular diseases characterized by proteinuria. Beyond its lead program, Chinook's investigational pipeline includes BION-1301, an anti-APRIL monoclonal antibody, which is presently being evaluated in a Phase I/II study for IgA nephropathy. Another promising candidate is CHK-336, an oral small molecule designed to inhibit LDHA, intended for patients with primary hyperoxaluria. The firm also maintains active research initiatives exploring solutions for other uncommon and severe chronic kidney ailments. Chinook Therapeutics, Inc. is based in Seattle, Washington.
Harga Saham
$40.39
Terakhir disinkronkan: 2023-08-18
Kapitalisasi Pasar
$1.70B
Perubahan (1 hari)
0.00%
Perubahan (1 tahun)
0.00%
Negara
US
Perdagangan Chinook Therapeutics, Inc. (KDNY)

Kategori

Riwayat hasil dividen untuk Chinook Therapeutics, Inc. (KDNY)
Hasil dividen (TTM) dari Chinook Therapeutics, Inc. (simbol saham: KDNY) per 2026: 0
Rata-rata hasil dividen selama 5 tahun terakhir: 0.00%
Riwayat hasil dividen untuk Chinook Therapeutics, Inc. (KDNY) dari 2026 hingga 2026
Hasil dividen pada akhir setiap tahun (TTM)
Tahun Hasil Dividen Mengubah
Tidak cukup data untuk tanggal yang disediakan.
Hasil dividen (TTM) untuk perusahaan serupa atau pesaing
Perusahaan Hasil Dividen Negara
0.00%
US
0.00%
NL
3.12%
AU
0.00%
US
0.00%
CH